Bispecific Antibody Efficacy and Safety in Multiple Myeloma: Updates from ASH 2025

EP: 1.Unmet Needs and Emerging Therapeutic Advances in Multiple Myeloma

EP: 2.Challenges in the Management of Relapsed/Refractory Multiple Myeloma

EP: 3.Addressing Therapeutic Gaps in Multiple Myeloma with Bispecific Antibody Therapies

EP: 4.Bispecific Antibodies in Multiple Myeloma and Practical Definitions of Lines of Therapy

EP: 5.Mechanisms of Action of Bispecific Antibodies in Multiple Myeloma

EP: 6.Evaluating Clinical Trial Data and Real-World Evidence of Bispecific Antibodies in Multiple Myeloma

Now Viewing

EP: 7.Bispecific Antibody Efficacy and Safety in Multiple Myeloma: Updates from ASH 2025

EP: 8.Clinical Insights on the Efficacy and Safety of Bispecific Antibodies in Multiple Myeloma

In this episode, experts review several ASH 2025 Annual Meeting abstracts that provide new insight into the efficacy and safety of bispecific antibodies. Panelists highlight real world data on teclistamab, showing that frail and trial-ineligible patients from a rural cohort achieved response rates around 63%, similar to pivotal studies. They note that patients typically declare response within three months, allowing clinicians to discontinue therapy early in nonresponders. Experts also describe findings that once patients on teclistamab reach their deepest response, extending dosing intervals can maintain outcomes. The discussion includes additional updates on linvoseltamab combinations with anti-CD38 antibodies such as daratumumab or isatuximab, which demonstrate encouraging safety and efficacy signals. Data on talquetamab in heavily pretreated populations show response rates exceeding 70% even among those with high-risk disease. Panelists also comment on reduced efficacy after prior CAR T or bispecific exposure and emphasize the value of real world evidence in shaping future trial design.